-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Sign up for news updates
-
Sustained Funding Vital for Smoking-Cessation Efforts
By Leah K. LawrencePosted: August 21, 2020 In July 2019, England’s government announced its goal to make the country “smoke free” by 2030.1 That may be easier said than done, however, according to a new joint report put out by Action on Smoking Health (ASH) and Cancer Research UK (CRUK).2 The annual report showed that…
-
Expanding Efforts Help Address Disparities in Lung Cancer Care
By Kara Nyberg, PhD Posted: August 21, 2020 A multitude of factors contribute to disparities in lung cancer care, including sex, race, education level, income, geographic region, and access to care. “There are some systemic barriers that make it difficult for people to obtain equitable treatment by race and class in the United States,” regardless…
-
An Early Look at Adjuvant Osimertinib Shows a Dramatic Improvement in Disease-Free Survival
By Mary Jo Fidler, MD Posted: August 21, 2020 At the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program Plenary Session, an early look at data from the ADAURA trial revealed very promising results.1 This phase III randomized trial in patients with resected EGFR-mutated NSCLC compared post-operative osimertinib to placebo for stage IB-IIIA…
-
Anne-Marie Baird, BSc, PhD
Posted: August 21, 2020 In addition to her role as a senior research fellow in Trinity College Dublin, Anne-Marie Baird, BSc, PhD, has been elected as the new president of Lung Cancer Europe (LuCE). LuCE is a non-profit umbrella organization that aims to provide a voice for people impacted by lung cancer in Europe. Dr.…
-
Expanding Efforts Help Address Disparities in Lung Cancer Care
By Kara Nyberg, PhD Posted: August 19, 2020 A multitude of factors contribute to disparities in lung cancer care, including sex, race, education level, income, geographic region, and access to care. “There are some systemic barriers that make it difficult for people to obtain equitable treatment by race and class in the United States,” regardless…
-
Brain Metastases in NSCLC: Is Delaying Upfront Radiation a Viable Option?
By Arya Amini, MD, and Chad G. Rusthoven, MD Posted: August 19, 2020 Approximately 10% of patients diagnosed with metastatic NSCLC present with brain metastases, and another 30% develop brain metastases during the course of their illness.1 Traditionally, the treatment for brain metastases included surgery, whole-brain radiotherapy (WBRT), or stereotactic radiosurgery (SRS). Due to neurocognitive…
-
A Roadmap to Improving Lung Cancer Care in the Middle East and North Africa
By Abdul Rahman Jazieh, MD, MPH Posted: August 21, 2020 Countries in the Middle East and North Africa region have significant variation in their socioeconomic status, healthcare resources, infrastructure, and approaches to healthcare provisions. The burden of lung cancer in these countries is huge, and it is only going to increase in the foreseeable future.…
-
Managing lung cancer in the time of COVID-19
Register Now REGISTER NOW for the Medscape Education and IASLC Exclusive Webinar: Immunotherapy and the COVID-19 Pandemic: Addressing Clinical Case Challenges in Lung Cancer on Tuesday, August 11, 2020 @ 8:00 am EDT. This webinar will discuss the key issues regarding the use of immunotherapy today, including how and when to start and stop therapy,…
-
Dr. Harpreet Singh Discusses the Conduct of FDA Clinical Trials During the COVID-19 Pandemic
Harpreet Singh, MD, is director of Division of Oncology 2 at the U.S. Food and Drug Administration (FDA). In the following interview, she discusses the FDA’s response to the COVID-19 pandemic in how clinical trials are conducted, as well as the implications of these changes and what can be expected going forward. Q: How has…
-
Lung Cancer Surgery in the COVID-19 Era: What Has Changed?
By José Francisco Corona-Cruz, MD We are living in an uncertain world in which the impact, timeline, and duration of the COVID-19 pandemic remain mostly unknown. This has led to dramatic changes in medical practice, with an unbalanced competition between SARS-CoV-2 on one side and most diseases on the other.1 For many patients with lung…
View ILCN Archives
Provider Resources
Popular Articles